Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safusidenib in Grade 2 IDH1-Mutant Glioma
NCT07712757Phase 3Not yet recruiting
- Sponsor
- Nuvation Bio
- Start
- Mar 2027
- Primary completion
- May 2029
01
Overview
A Phase 3 trial of safusidenib in glioma, sponsored by Nuvation Bio. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
safusidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07712757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07712757.